F			· ·									
FOR	M PT	0-144	9 (			30727.0013.0			SERI 00/5			-
1/4	<b>EFO</b>	PATE	ENTS AND OTHER I RMATION DISCLOS	TEMS FOR A	PPLICANT'S	APPLICANT:						
6		ʹቈ.			15	METABASIS FILING DATE:	THE	_	GRO		INC.	
Albi-	118		Jse several sheets i	7 necessary	111	March 5, 199	<u> </u>		1614			
No.		115)		-	<del></del>			·				
	TRAD		<del></del>									
2	MINER	T	<u> </u>	U.S. P	PATENT DOCU	IMENTS			·			
INI	TDAL		DOCUMENT NUMBER	DATE		IAME	a	ASS		UB ASS		LING ATE
	pr	A	3,018,302	01.23.62	Bielefeld, e	t al						
		AB	5,157,027	10/20 92	Biller, et al.							
LA	/_	AC	5,658,889	8/19/97	Gruber, et a	1.						· · · · · ·
_ <del>,</del>	l								<del></del>		· <b>L</b>	
				POREIGN	N PATENT DO	CUMENTS			<u>-</u>			
EXAM INI	IINER ITAL		DOCUMENT NUMBER	DATE			Γ		SU		TRANS	LATION
a	M	AD	0 002 062 A	30.05.78	EP (Abstract	JNTRY	a	ASS	_aA	S	YES	NO
		AE	0 072 531 A	23,62.83	EP (Abstract							
	_	AF	0 158 057 A	16.10.85	EP (Abstract					-		
	-	AG	0 180 276	28.12.88	EP (Abstract		Н		+	+		<del></del>
		АН	0 261/283			$\overline{}$	$\vdash$		-	$\dashv$		
				22.09.86	EP		Н		+	$\dashv$		
			0∕161 955 A	21.11.85	EPO							
		AY	0 338 372 A	25.10.89	EPO				4	_		
	4	AK	0 353 692 A	07.02.90	EPO				1	.		
4		AL	0 481 214 A	22.04.92	EPO				1	$\bigvee$		
-N	/	AM	492 738 A	30.06.70	СН				$\perp$	Y		
<u>V</u>		AN	16 93 219 <sub>4</sub> A	17.09.70	DE (Abstract)	1						
			0	Que	MICE	ille		,				
EXAMI	DATE CONSIDÈRED: 7/9/0-											
!!!	ioagii	CHAIL	tial if reference is co on if not in conform applicant	onsidered, w ance and no	hether or not cit t considered. In	ation is in confor	man his f	ce wi	th MI vith n	PEP 6	609; Dr	8W

Informati n Discl sure Statement -- Secti n 9 PTO-1449

			•			~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~						
FORM (			`	*		ATTY. DOC 37				1al n 518,5		
	18	NFOR	nts and other in Mation disclosi	JRE STATEM	applicant:							
STORY OF THE PROPERTY OF THE P	E	<b>(49)</b>	es saveral sheets i	i necessary)		FILING DATE: March 5, 1999			GRC 161	UP:		
	FOREIGH PATENT DOCUMENTS											
۱ ۵.	4.											
EXAMINA INITIAL	ige.	RADE	DOCUMENT NUMBER	DATE	α	UNTRY	a	ASS		RUB .ass	TRANSLATION NO	
K		AO	35 12 781 A1	10.04.85	DE (and End U.S. Patent	glish language No. 4,952,740)						
	$\supset$	AP	96/01267 A	18.01.96	wo							
		ACA	97/03679 A	06.02.97	wo							
•		AR	98:09668 A	12.03.98	WO	/.						
		AS	98/39342	11.09.98	wo							
		AT	98/39343	11.09.98	wo /							
W		AU	98/39344	1.09.98	WO				П			
									1	<del></del>		
	(	OTKE	er documents	(Including	g Author, Til	de, Date, Perti	ner	nt Pa	ages	, etc	.)	
gr	A	V_	"Patent Abstracti (Yamishata Koji;	s of Japan," Nippon Soc	Vol. 1998, No da Co. Ed), 10	o. 1, 30 January 6 September 199	199 97	98 &	JP (	09 24	1284 A	·
	Al	w	DeLombaert, et a New Generation Chem. 37: 498-5	on of Neutra	phonomethyl I Endoprptide	Dipeptides and 1 (NEP, EC 3.4	The .24	ir Pt .11)	nosp Inhil	honai bitors	te Prod , <u>J. Med</u>	rugs, <u>1</u>
	Edmunson, et al., "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2λ5-dioxaphosphorinane Series. X-Ray Molecular Structure of cis-2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-Oxide," J. Chem. Res. Synop., 5: 122-123 (1989)											
	AY	,	Farquhar, et al., "5'-'4-(Pivaloyloxy)-1, 3, 2-dioxaphosphorin an -2-y]I-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FDUMP)'" J. Med. Chem. 38:488-495 (1995)									
4	AZ		Farquhar, et al., 172(3): 3/24 (1983)	Biologically			tive	Gr	oups	," <u>J. F</u>	Pharm.	Sci.

Examiner: DATE CONSIDERED: DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

Form Pi		$\smile$	ATTY. 006 7 MO. 30727.0013.CIP1	Serial No. 09/518,501					
LIST 0		nts and other items for applicant's	applicant:						
PE	aronda <b>?</b> .	Mation disclosure statement	METABASIS THERAPEUTICS, INC.						
<b>∕</b> ⊘″. ′	c, &\ (⊍	se several sheets if necessary)	Filing Date: March 5, 1999	Group: 1614					
	March 5, 1999 1614								
My									
<b>A</b>	NI IO	er Documents (Including Author, Ti	de, Date, Perdinent I	Pages, etc.)					
FRADE PRADE		Farquhar, et al., "Synthesis and Biologica	il Evaluation of 9-[5'-(2-	-Охо-1.3 <i>.2-</i>					
	oxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine and 9-[5'-(2-0x0-1,3,2-								
		dioxazaphosphorinan-2-yl)-B-D-arabinos	Aladenine: Potential No	swifal Precursors of 9-					
du	BA	(8-D-Arabinofuranosyl)adenine 5'-Monop	hosphate," <u>J. Med. Che</u>	<u>em.</u> 28: 1358-1361					
<b>├──</b>	DA	(1985)	<del></del>						
	88	Farquhar, et al., "Synthesis and Biologica Puoro-2'-deoxyuridine 5'-Phosphate," J.	New Character of Neutral	Derivatives of 5-					
<del></del>	00								
		Freed et al., "Evidence For Acyloxymeth	yl Esters of Pyrimidine	5'-					
1.	ВС	Deoxymbonucleotides as Extracellular So	Mices of Active 5'-Deox	cyribonucleolides in					
	BC Cultured Cells," Biochem. Pharmac. 38. 3193-3198 (1989)  Hillers, et al., "Analogs of pyrimidine mono-and polynucleotides. IV. Phosphates of 1-								
	(1,4-dihydroxy-2-pentyl)thymine and 1-(1,3-dihydroxy-2-propyl) uracil." Khim Geterotski								
	BD Soedin 5:678-683 (1978). Cham Abst. v 89 no 17; abst no 146864a								
	Hunston, et al., "Synthesis and Biological Properties of Some Cyclic Phosphotriesters  BE Derived from 2'-Deoxy 5-flagorouridine," J. Med. Chem. 27: 440-444 (1984)								
	BF	Kryuchkov, et al. 1zv. Akad. Nauk SSSR.	Ser. Khim. 6: 1201-12	48 (1987)					
		Lok, et al., "Neurotoxicity associated with	adenine arabinoside m	onophosphate in the					
	8G	treatment of chronic hepatitis B virus infect (1984)	ction," <u>J. Antimicrob. Ct</u>	nemotherap. 14: 93-99					
	BG								
		Ludeman, et al., "Synthesis and Antitumo	r Activity of Cyclophos	phamide Analogues. 4.					
		Preparation, Kinetic Studies, and Anticand	cer Screening of "Phen	vi ketophos phamide"					
	BH /	and Similar Compounds Related to the Cy Aldophosphamide," J. Med Chem. 29, 716	yciopnospnamide ivieta S-727 (4886)	bolyte					
.		Meier, et al., "Cyclic Saligenyl Phosphotre	isters of 2', 3'-Dideoxy	2', 3'-					
	81	didehydrothymidine (d4T) - A New Pro-No Lett. 7: 99-104 (1977)	ncieogoe Abbusacu' Bi	oorg. Med. Chem.					
	-								
	BJ	Meyer, et al., "2"-O'-Acyl-8-thioinosine Cyl Thioinosinic Acid," J. Med. Chem. 22: 811	-815 (1979)						
	/	Neidlein, et al., "Mild Preparation of 1-Ben	zyloxyiminoalkylphosp	honia Dichlorides:					
N		Application to the Synthesis of Cyclic Pho	sphonic Deisters and C	yclic Monoester					
	BK	Amides," histerocycles 35: 1185-1203 (19	93)						
<del></del>	$\rightarrow \downarrow$	ATIL CHANGE	alos						
EXAMINER:	<u> </u>	DATE OF THE DATE	CONSIDERED:						
Examiner									
EXAMINI	ER: Init	tial if reference is considered, whether or not ci	tation is in conformat	with MADED 400. D					
line throug	h citatio	on if not in conformance and not considered. In	uclude a copy of this form	with next					
communic	ation to	applicant		,					

FORM P	TO-1449		ATTY. DOC T NO.	SERIAL NO.			
			30727.0013.CIP1	09/518,501			
UST O		INTS AND OTHER ITEMS FOR APPLICANT'S IMATION DISCLOSURE STATEMENT	APPLICANT: METABASIS THERA	APEUTICS, INC.			
6,,,	اربر البرانية البرانية	ise several sheets if necessary)	FILING DATE: March 5, 1999	<b>GROUP:</b> 1614			
10H 1 1	2						
	<b>ATH</b>	IER DOCUMENTS (Including Author, T	itle, Date, Pertinent	Pages, etc.)			
gri	BL	Nifant'ev, et al., "1,3,2, - Diazaphodspho 1979, Pages 64-74 (and English version Language publication)	orinanes", <u>Zh. Obshch.</u> as translated in corres	Khim., Vol. 49, No. 1, ponding English			
	BM	Nifantyev, et al., "Synthesis and Structure of Some Stable Phospholane- Phospholanes," Phos. Sulfur & Silicon 113, 1-13 (1996)					
	BN	Predvoditelev D., et al., "Glycero-2-hydroxymethylene phosphates" <u>Journal of Organic</u> Chemistry of the USSR (English Translation 13:1489-1492 (1977))					
		Predvoditelev, D. et al., "Synthesis of Jipids and their models on the basis of glycerol					

phosphatidylhydroxyhomocholipe Journal of Organic Chemistry of the USSR (English

Shaw & Cundy, "Biological Screens of PMEA Prodrugs," Pharm. Res. 10 (Suppl) S24

Starrett, et al., "Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)-ethyl]adenine (PMEA)," J.

Yamanaka, et al., "Metabolic Studies on BMS-200475, a New Antiviral Comound Active against Hepatitis B Virus," Antimicrob. Agents Chemoth. 43, 190-193 (1999)

Zon, ét al., "4 Cyclophosphamide Analogues," Prog. Med. Chem. 19: 205-246 (1982)

Shih, et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," Bull. Inst. Chem. Acad. Str. 41: 9-16 (1994)

alkylene phosphites. V. Cyclic phosphatidylglycerol and

Translation 17:1156-1165 (1981)

Med. Chem. 37: 1957-1864 (1994)

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

BO

BP

BQ

BR

BT

(1993)

Please type e plus sign (\*) Under the Papararett Reduction Act of 19Es

Sheet

FB 25 M 3

Approved for Suph 10/31/2002 OMB 6851-0031

Approved for Suph 10/31/2002 OMB 6851-0031

OEPARTMENT OF COMMERCE

and are required to rest and to a collection of information unitable contains a verild OMB control number

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO

THANK THANK Information disclosure STATEMENT BY APPLICANT

Complete If Known Application Number 09/318,501 Filing Date

March 3, 2000 Erlan First Named Inventor Group Art Unit 1624

(use as many sheets as necessary) of

T. McKenzie Examiner Name 030727.0013.CIP1 Attorney Docket Number

U.S. PATENT DOCUMENTS gera, Cerumno, Urcos, Winco Rodoveni secogos er Rodoveni Oato of Publication of U.S. Patent Occument Nome of Patentee or Applicant of Cited Document Chia No." Cited Document Examinar Hand Could' (If brown) Initiato" Number MH-DD-YYYY

	Foreign patent documents								
			Foreign Patent Doc	ument	Nums of Patentes or	Date of Publication of	Poges, Columns, Lifess, West Baltones	1	
Exember Taltfale	Cits No. <sup>1</sup>	Officer	Number	icent Cota (f.	Applicant of Cited Document	Cited Decument MM-DD-YYYY	Parente or Reference Figures Appear	70	
								L	
								╙	
						<u> </u>		┼	
						<u> </u>		┿	
		T - 1				<u> </u>	<del></del>	느	

	NON PATENT LITERATURE DOCUMENTS									
Examinar Initials		Cite No.'	includo nama of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the litern (book, magazina, formot, sarici, symposium, catalog, etc.), date, page(s), volume-lesue numbor(s), publisher, city and/or country where published.	72						
PA AA		AA	Coppi, et al., "Lewis Acid Mediated Condensation of Alkenols and Aldehydes. A Selective Synthesis of Tetrahydropyrans and Oxepanes," J. Org. Chem., Vol. 53, No. 4, 911-913 (1988)							
		AB	Lohr et al., "Targeted chemotherapy by intratumor injection of encapsulated cells engineered to produce CYP2B1, and ifosfamide activating cytochrome P450," Gene Therapy, 5, 1070-1078 (1988).							
1		AC	Bijsterbosch, et al., "Disposition of the Acyclic Nucleoside Phsophonate (S)-9-(3- Hydroxy-2-Phosphonylmethoxypropyl)Adenine," Antimicrobial Agents and Chemotherapy, "Vol. 42, p. 1146-1150 (May 1998).							
V	$\prod$	AD	de Waziers, et al., "Cytochrome P 450 Isoenzymes, Epoxide Hydrolase and Glutathione Transferases in Rat and Human Hepatic and Extrahepatic Tissues1," The Journal of Phermacology and Experimental Therapeutics, Vol. 253, No.1, p. 387-394 (1989).							

Examiner Dis Mallos Signature Dis Mallos	Oate Considered	2/12	03

\*EXAMPLES: Initial if reference considered, whether or not citation is in conformance with MPEP 609. One line through distinct in not in conformance and not considered, include copy of the regression in next communication to applicant.

\*Unique distilen designation number. \* See exacted Kinds of U.S. Petent Decuments. \* Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the relign of the Emparer must precede the certain number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. \* Applicant is to place a chack mark here if English language Translation is standard.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the emount of time you are required to complete this form should be cent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patenta, Washington, OC 20231.

Pissse type a plus sign (+) inside this box 🤜

PTO/SB/08A (08-00) Approved for 20though 10/31/2002, CMB 0351-0031
Patent and Tredemark Office: U.S. DEPARTMENT OF COMMERCE

Petent and Tradamark Office: U.S. DEPARTIMENT OF COMPANY AND CONTROL OF COMPANY OF COMP Under the Peperwork Reduction Act of 1985, no pa

Substitute for form 1449A/PTO

TRANFUR

INFORMATION DISCLOSURE

**Application Number** 09/518,501 Filing Date March 5, 1999 First Named Inventor Erion **Group Art Unit** 1824 T. McKenzie Examiner Name

Complete If Known

(USO 83 many shoets 83 necessary)

Sheet of

STATEMENT BY APPLICANT

**Atternsy Docket Number** 030727.0013.CIP1 NON PATENT LITERATURE DOCUMENTS include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journel, serial, symposium, catalog, etc.), date, paga(s), volume/asse number(s), publisher, city and/or country where published. Cite No. He, et al., "Inactivation of Cytochrome P450 3A4 by Bergamottin a Component of

שער		Grapefruit Juice," Chem. Res. Toxicol, Vol. 11, No. 4, p. 252-259 (1998).	
8	AF	Jounaidi et al., "Retroviral Transfer of Human Cytochrome P450 Genes for Oxazaphosphorine-based Cancer Gene Tharapy," Cancer Research, Vol. 58, p. 4391-4401 (Oct. 1, 1998).	
			1
		·	I
			1
			-
			+

		1	
Examiner Signature	Date	2/13	/25
	Considered		/ 0.5

Burden Hour Sistemant: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the IndiMdual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Weshington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents.

<sup>\*</sup>EXAMIRER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. \* See attached Kinds of U.S. Patent Documents. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the retign of the Emperor must precede the certal number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \* Applicant is to place a check mark here if English language Translation is ettached.

•										
FORM PT	-				ATTY. DOCY 30727.001		<b>SERIAL NO</b> 09/518,50			
LISTO		NTS AND OTHER IT MATION DISCLOSU			APPLICANT: METABASI		EUTICS, I	INC.		
#U	(U:	se several sheets if	necessary)		FILING DATE: GROUP: March 5, 1999					
		1341 O	•				20	<b></b>		
L	7	FER 2 5 2007 55	•				MAR	VEN		
	PATE		U.S. PA	TENT DOC	UMENTS	"ECH	CENTER 10	7002		
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	GASS OF	FILING DATE		
10	U AA	3,018,302	01/23/62	Bielefeld,	et al.	260	46	300		
M	4 AB	5,157,027	10/20/92	Biller, et al	) <b>.</b>	514	167			
10	W AC	5,658,889	8/19/97	Gruber, et	al.	514	43			

•	FOREIGN PATENT DOCUMENTS									
EXAMINER				T T			SUB		TRANSLATION	
INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	<u>a</u>	22	CA	22	YES	NO
TUM	AD	0 002 062 A1	30.05.79	EP (and English language - Abstract)						
TU	AE	0 072 531 A1	23.02.83	EP (and English language Abstract)						
CM	AF	0 158 057 A	16.10.85	EP (U.K. English language translation)		·				
	AG	0 180 276 A1	28.12.88	EP						
	AH	0 261 283 A1	22.09.86	EP						
	Al	0 161 955 A1	21.11.85	EPO						
	AJ	0 338 372 A2	25.10.89	EPO						
	AK	0 353 692 A2	07.02.90	EPO						
	AL	0 481 214 B1	22.04.92	EPO						
	AM	492 738	30.06.70	CH (and English language Abstract)						
$\bigvee$	AN	987,378	17.09.70	UK						

EXAMINER:	DATE CONSIDERED	18/8/S
EXAMINER: Initial if reference is	ensidered, whether or not citation is in c	conformatice with MPEP 609; Drav
hine through citation if not in conform communication to applicant	ance and not considered. Include a cop	py of this form with next

# FORM PTO-1449 LIST OF PATERTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheeten) (correction) ATTY. DOCKS NO. 30727.00 (IP1 09/518,501 APPLICANT: METABASIS THERAPEUTICS, INC. FILING DATE: GROUP: 1614

			i fortaisk	PATENT DOCUMENTS				HAA		VE
EXAMINER INITIAL		DOCUMENT NUMBER	PANAN POPUL	COUNTRY	a	355_	FCF		YES	ORO_
M	AO	35 12 781 A1	10.04.85	DE (and English language U.S. Patent No. 4,952,740)				-10/	A 1600,	ATION OUT OF THE PROPERTY OF T
	AP	96/01287	18.01.96	wo						
	AQ	97/03679	06.02.97	wo		L				
	AR	98/09668	12.03.98	wo		<u> </u>				
	AS	98/39342	11.09.98	wo					··	
7	AT	98/39343	11.09.98	wo						
	AU	98/39344	11.09.98	wo						

	OTHER DOCUMENTS (Including Author, Tide, Date, Perdinent Pages, etc.)								
"Patent Abstracts of Japan," Vol. 1998, No. 1, 30 January 1998 & JP 09241284 A (Yamishata Koji, et al.; Nippon Soda Co. Ltd), 16 September 1997									
DeLombaert, et al., "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrug a New Generation of Neutral Endoproptidase (NEP, EC 3.4.24.11) Inhibitors, J. Med. AW Chem. 37: 498-511 (1994)									
	AX	Edmunson, et al., "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2λ5-dioxaphosphorinane Series. X-Ray Molecular Structure of cis-2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-Oxide," J. Chem. Res. Synop., 5: 122-123 (1989)							
	AY	Farquhar, et al., "5'-'4-(Pivaloyloxy)-1, 3, 2-dioxaphosphorin an -2-y]i-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FDUMP)" J. Med. Chem. 38:468-495 (1995)							
V	AZ	Farquhar, et al., "Biologically Reversible Phosphate-Protective Groups," <u>J. Pharm. Sci.</u> 72(3): 324-325 (1983)							

EXAMINER:	Mar Vest	MM	19	DATE CONSIDERED:	glor
EXAMINER: line through c communication	itation if not in o	nce is considered; conformance and	whether or not consider	not citation is in conto red. Include a copy of	rmance with MPEP 609; Draw this form with next

FORM PYO-1449	ATTY. DOCKST NO. 30727.001 IP1	serial no. 09/518.501
List of patents and other items for applicants information disclosure statement 5 2002	Applicant: METABASIS THERA	A
(Uso several sheets if necessity)	Filing Date: March 5, 1999	GROUP: CELV
A TOP WILLIAM		IBUFA WO .

	- · · · ·	16UTES TO 2
	OTH	ER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  Farquhar, et al., "Synthesis and Biological Evaluation of 9-[5'-(2-0xo-1.3.2-
W	BA	Farquhar, et al., "Synthesis and Biological Evaluation of 9-[5'-(2-Oxo-1,3,2-0xazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine and 9-[5'-(2-Oxo-1,3,2-dioxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine: Potential Neutral Precursors of 9-[ß-D-Arabinofuranosyl]adenine 5'-Monophosphate," J. Med. Chem. 28: 1358-1361 (1985)
	88	Farguhar, et al., "Synthesis and Biological Evaluation of Neutral Derivatives of 5-Fluoro-2'-deoxyuridine 5'-Phosphate," J. Med. Chem. 26: 1153-1158 (1983)
	BC	Freed, et al., "Evidence For Acyloxymethyl Esters of Pyrimidine 5'- Deoxyribonucleotides as Extracellular Sources of Active 5'-Deoxyribonucleotides in Cultured Cells," Biochem. Pharmac. 38: 3193-3198 (1989)
	BD	Hillers, et al., "Analogs of pyrimidinemono-and polynucleotides. IV. Phosphates of 1-(1,4-dihydroxy-2-pentyl)thymine and 1-(1,3-dihydroxy-2-propyl) uracil." Khim Geterotski Soedin 5:678-683 (1978). Chem Abst. v 89 no 17; abst no 146864 g/u,
	BE	Hunston, et al., "Synthesis and Biological Properties of Some Cyclic Phosphotriesters Derived from 2'-Deoxy-5-fluorouridine," J. Med. Chem. 27: 440-444 (1984)
	BF	Kryuchkov, et al., Izv. Akad. Nauk SSSR, Ser. Khim. 6: 1201-1248 (1987)
	₿G	Lok, et al., "Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection," <u>J. Antimicrob. Chemotherap.</u> 14: 93-99 (1984)
·	вн	Ludeman, et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenyl ketophos phamide" and Similar Compounds Related to the Cyclophosphamide Metabolyte Aldophosphamide," J. Med Chem. 29, 716-727 (1986)
	81	Meier, et al., "Cyclic Saligenyl Phosphotreisters of 2', 3'-Dideoxy-2', 3'-didehydrothymidine (d4T) – A New Pro-Nucleotide Approach," <u>Bioorg. Med. Chem.</u> <u>Lett.</u> 7: 99-104 (1997)
	BJ	Meyer, et al., "2"-O'-Acyl-6-thioinosine Cyclic 3', 5'-Phosphates as Prodrugs of Thioinosinic Acid," J. Med. Cham. 22: 811-815 (1979)
	8K	Neldlein, et al., "Mild Preparation of 1-Benzyloxyiminoalkylphosphonic Dichlorides: Application to the Synthesis of Cyclic Phosphonic Deisters and Cyclic Monoester Amides," Heterocycles 35: 1185-1203 (1993)

Examines:	DATE CONSIDERED: 7/9/02	~
EXAMINER: Initial if reference is considered	ed, whether or not citation is in conformance with MP and not considered. Include a copy of this form with ne	

٠	٠						
_	CRM PT			ATTY. DOCKET NO. 30727.001 P1 09/518,501			
	LIST 0	F PATEN INFORI	ITS AND OTHER ITEMS FOR APPLICATES MATION DISCLOSURE STATEMEND	APPLICANT: METABASIS THERA	PEUTIOS INC.		
		(Us	se several sheets if necessary) FB 2 5 mm 2	FILING DATE: March 5, 1999	GROUP: CE/VE 1614 MAP 0 2 2002		
_					Tra "102 5/		
		ОТН	ER DOCUMENTS (Including 40 those) Ti	tle, Date, Pertinent	Pages (A) 2002		
	pu	BL	Nifant'ev, et al., "1,3,2, - Diazaphodsphor 1979, Pages 53-61.	rinanes", <u>Zh. Obshch. k</u>	(him., Vol. 49, NG/2900		
		ВМ	of Some Stable Phosp 3, 1-13 (1996)	pholane-			
		Predvoditelev D., et al., "Glycero-2-hydroxymethylene phosphates" <u>Journal of Chemistry of the USSR (English Translation</u> 13:1489-1492 (1977))					
Predvoditelev, D. et al., "Synthesis of lipids and their models on the basis of alkylene phosphites. V. Cyclic phosphatidylglycerol and phosphatidylhydroxyhomocholine" <u>Journal of Organic Chemistry of the US</u> BO Translation 17:1156-1165 (1981)							
		BP ·	Shaw & Cundy, "Biological Screens of Pl S-294 (1993)	MEA Prodrugs," Pharm	. Res. 10 (Suppl)		
		BQ	Shih, et al., "Preparation and Structures of dioxaphosphorinane-2-oxides," Bull. Inst.	of 2-Dimethylamino-4-p Chem. Acad. Sin, 41:	ohenyl-1,3,2- 9-16 (1994)		
		BR	Starrett, et al., "Synthesis, Oral Bioavaila Prodrugs of the Antiviral Agent 9-[2-(Pho- Med. Chem. 37: 1857-1864 (1994)	bility Determination, an sphonomethoxy)-ethy[]	d <i>in Vitr</i> o Evaluation of adenine (PMEA)," <u>J.</u>		

Yamanaka, et al., "Metabolic Studies on BMS-200475, a New Antiviral Comound Active against Hepatitis B Virus," Antimicrob. Agents Chemoth. 43, 190-193 (1999)

Zon, et al., "4 Cyclophosphamide Analogues," Prog. Med. Chem. 19: 205-246 (1982)

EXAMINER:\	_ **	$\cap M$	[ <i>]</i> [. •	DATE CONSIDERED:	10/-			
Example	Monde	1 14/1/	XX	7	19/8			
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw								
line through citation if not in conformance and not considered. Include a copy of this form with next								
communication to applicant								

BS

rps ( pius eign (+) inside this boss 💠 💠 भूत अस्त्रि Substitute for form 1446APTO Complete If Resum Application Number 09/518,501 INFORMATION DISCLOSURE March 3, 2000 Filling Deto STATEMENT BY APPLICANT First Named Inventor Erion et al. Group Art Unit 1824 (use as many sheets as necessary) Examiner Name McKanzia, T. Alternay Decitet Number 45198,00013.RCE (CIP1) Sheet 01

				U.S. PATENT DOCU		
matro: Malo	84	Nu.8. Patent (	Contract Con	Manus of Patenton or Applicant of Cited Decument	Onto of Publishment Charle Consumers MM-OD-YYYY	Pogon, Galvaren, Llein, Warro Reforme Ponnegus er Actuven Rivusta Appeer
925		6,054,587		Reddy et al.	04/25/00	·
		6,110,903		Kasibhatla et al.	08/29/00	
		6,284,748		Dang et al.	09/04/01	
		6,294,672		Reddy et al.	09/25/01	
		6,312,662		Erion et al.	11/05/01	
		6,399,782		Kasibhatla et al.	06/04/02	
V		6,489,476		Dang et al.	12/03/02	
						,

l	FOREIGN PATENT DOCUMENTS										
Evening	Cite		Foreign Palent Doc		Native of Potentine or	Date of Publication of	Payer, Calimana, Libra, Where University				
Exerciser loideds	Na.	Office	Number*	pramm) AFFI (SAFA (A	Applient of Cital Document	Cited Decement MM-00-YYYY	Possacial or Districts Riginato Appear	75			
								$\Box$			
		لـــا									

Non Patent Literature documents									
Exemples Indicto	Cabo Na.'	Declara recorse of the cusher (in CAPITAL LETTERS), title of the order (schen coprogratio), title of the term (in CAPITAL LETTERS), title of the order country of the count	79						

Examinge Our Machel Considered 4/16/04	 <b>-</b>		 	
	Jon	Meldo	9/16	104

"EXAMINER: Intelligible in retaining considered, whether or not provide in in contamination with his EP 608. Javes line discuss a listing to not in contamination and contamination in contamination.

"Unique elicition designation number." See disental Rimos et U.S., Patent Consumanta. "Enter Calco Unat bousel fire descument, by the bro-losser code (WPO Sendere 87.3). "For Japanere potent descument, his latination et the year et the clayer et the Engage mass present the codes remains et the patent descument." Rimd et descument by the coprophole symbols on Indicated on the decument under WIPO Standard 87, 16 8 possible. "Applicant to to place o check mark there it English Broguege Transform to attached.

Burdan Hour Statement. This form is cotinated to into 2.0 from to complete. Time will very departing upon the needed of the individual case. Any commonts on the amount of time you are required to complete this form chould be can to the Chief Intermeden Officer, V.S. Patent and Tradements Office, Whathington, OC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Accident Commiscionar for Patenta, Whathington, OC 20231.

Please type a plus sign (+) inside this box -> +

STENT!

Sheet

PTO/SB/GEA (08-09)

to type a plus sign (+) inside this box -> + Approved for use through 10/31/2002, OMB 0851-0931

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1895, no persons are required to respond to a collection of information unless it constains a valid GMB control number Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

> (use as many aheata as necessary) ol

Applicatives wis						
Application Number	09/518,501					
Filing Cate	March 3, 2000					
First Named Inventor	Erion et al.					
Group Art Unit	1624					
Examiner Name	T. McKenzie					
Attorney Docket Number	45188.00013.RCE					

			U.S. PATENT DOCU	MENTS					
Cite No."	U.S. Patent Document Number . Red Code*		I Gnd Code <sup>3</sup>		10nd Code <sup>2</sup>		IOnd Code Name of Printing of Applicant		Pages, Coherra, Ures, Where Rativari Palanges or Retevari Pagesya Appear
					•				
		ļ							
			· ·		<del></del>				
		Ш			,				
		_							
	Citie No.'	No. 1	No. 1 Idea Code	Cite No.  U.S. Patent Document No.  Number - Ind Code of Cited Document of Cited Document	City D.S. Patent Document  No. Number - Rose Cool of Cited Document  Name of Patentes or Applicant of Cited Document  MM-OD-YYYY  MM-OD-YYYY				

			FOREIGN P.	ATENT DOCUMEN	rrs	· · · · · · · · · · · · · · · · · · ·	
City		Foreign Patent Doc		Mame of Patentee or	Date of Publication of	Pages, Coleman, Lime,	1
No.	Office	Number*	Goal Code' (//	Applicant of Clad Document	Cited Document MM-DD-YYYY	Where Referent Passages or Referent Figures Agrees	7
						-	1
	<b></b>					· · · · · · · · · · · · · · · · · · ·	
	Citz No.			Cite Foreign Palent Document	City Foreign Potent Document Name of Potenties or No.   Name of Potenties or Applicant of Clark	No. Coffee Number Card Cod W Applicant of Clark Color Document	Cite Foreign Potent Document Name of Publication of Publication of Publication of Publication of Vern Releases  No.   Officer Number Kind Code (/ Applicant of Clied Document When Releases)

	NON PATENT LITERATURE DOCUMENTS							
Exeminer Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the fiam (book, caspacine, journal, acrtal, symposium, catalog, etc.), date, page(a), volume-issue number(a), publisher, city and/or country where published.	79					
		FARQUHAR et al., "Synthesis and Antitumor Evaluation of Bis[pivaloyloxy)methyl] 2'-Deoxy-5-fluorouridine 5'-Monophosphate (FdUMP): A Strategy to Introduce Nucleotides into Cells," J. Med. Chem., 37:3902-3909 (1994).						
n		LEFEBVRE, et al., Mononucleotide Phosphotriester Derivatives with S-Acyl-2-thioethyl Bioreversible Phosphate-Protecting Groups: Intracellular Delivery of 3'-Azido-2',3'-dideoxythymidine 5'-Monophosphate," J. Med. Chem., 38:3941-3950 (1995).						

	<b></b>	$\Delta Z_{}$		/	/ ,
Examiner Signature	Dull !	lo .	Date Considered	4/16/	64
*EXAMINED- Instru	I softmann eans idead who			- ///	

and not considered. Include copy of this form with next communication to applicant.

"Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (MIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must proceed the serial number of the patent document. <sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>3</sup> Applicant is to place a check mark here if English language Translation is affected.

Burden Hour Statement: This term is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissionar for Patenta, Washington, DC 20231.

Ptsasa type o plus sign (+) inside this box -> 💠

PTO/SB/08A (08-00)

a type o plus vign (+) Inside this box -> + Approved for use Direugh 10/31/2002. DMB 0831-0001

U.S. Potent and Tractament Office: U.S. DEPARTMENT OF COMMERCE

Under the Papartment Rodustion Act of 1886, no pamens are required to respond to a expected of bitemestian unbox 8 contains a valid CMB central dumber

Substitute for form 1448A/PTO Complete II Known Application Number PEB 2 7 200% 09/518,501 nformation disclosure March 3, 2000 Statement by applicant First Named Inventor Erion ot al. STORE BY Group Art Unit 1624 (use as many sheets as nacessary) Examiner Name T. McKenzie of **Alterney Doctet Number** 032465.00013.RCE (CIP1)

				U.S. PATENT DOCU	MENTS	
Examinor Initiato*	Çile No.'	V.S. Patent Document  Number tens Cost ' V tens on				Pogos, Cabarros, Linos, Walto Robertos Podingos er Redevido Pipuros Apporer
·	<u> </u>					
<u></u>						
L	L	ہـــــــــــــــــــــــــــــــــــــ				

	~~~~			FOREIGN P	ATENT DOCUMEN	rs		$\overline{}$
Exeminer	Chr	<b></b> _	Foreign Patent Dox		. Name of Passages or	Date of Publication of	Popus, Column, Lices,	
laitich.	No.'	our	Number <sup>1</sup>	Miral Costs <sup>®</sup> (gf Account)	Applicant of Cited Constant	Cited Deserrans MM-DD-YYYY	Possess or Relations Possess or Relations Physical Agency	ہ
L								H
·								┝┈┤
<u> </u>	<del>                                     </del>					<del> </del>	<u>.</u>	Щ
<u></u>		<u>_</u>				<u></u>		

		( NON PATENT LITERATURE DOCUMENTS .	
Excursions traiting to	Cito No.'	Include norms of the author (IRCAPITAL LETTERS), title of the article (others exprepriate), title of the litem (book, magazina, journel, sorticl, symposium, cetalog, etc.), date, page(s), volume-bose number(s), publisher, city confor country where published.	F
81		Beaucage and Iyer, "The Synthesis of Modified Oligonucleotides by the Phosphoramidite Approach and Their Applications," Tetrahedron, 49(28):6123-6194 (1993).	
		Borch and Millard, "The Mechanism of Activation of 4-Hydroxycyclophosphamide," J. Med. Chem., 30:427-431 (1987).	
		Cooper et al., "Use of Carbohydrate Derivatives for Studies of Phosphorus Stereo-chemistry. Part II. Synthesis and Configurational Assignments of 1,-3,2-Oxathiaphosphorinan-2-ones and 1,3,2-Dioxaphosphorinan-2-thiones," <a href="https://doi.org/10.1049-1052">J. Chem. Soc., Perk. Trans. 1</a> , (10):1049-1052 (1974).	
		De Clercq et al., "A Novel Selective Broad-spectrum Anti-DNA Virus Agent," Nature, 323:464-467 (1986).	
U		Farquhar et al., "Synthesis and Antitumor Evaluation of Bis[(pivaloyloxy)methyl] 2'-Deoxy-5-fluorouridine 5'-Monophosphate (FdUMP): A Strategy to Introduce Nucleotides into Cells," J. Med. Chem., 37:3902-3909 (1994).	

Examinar Date Signature Considered

\*EX MANER: Instit if reference considered, whether or not distin to in conformance with MPEP 600. Drowylow through elisition to not in conformance and not considered. Institute copy of this form with next communication to explicant.

Surten Hour Statement: This form to estimated to take 2.0 hours to complete. This will vary depending upon the meads of the Individual case. Any comments on the armount of time you are cognized to complete this form should be sent to the Chief Information Officer, U.S. Patent and Tradement Officer, Washington, OC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>Unique clation designofism number. \* See attended kinds of U.S. Potent Decuments. \* Setter Calco that bound the decument, by the fee-fatter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the reign of the Emperor study precede the coded number of the petent document. \* Kind of document by the appropriate symbols as indicated on the document under vetical Standard ST. 16 if possible. \* Applicant is to place a document where it English English English English is absolved.

PTO/SB/084 (08-00) O type o give dign (+) Indide this box +> P Approved for uso Dresugh 1021/2002, CAS 0351-0331

U.S. Patent and Treatement Color: U.S. OEPARTIMENT OF COMMERCE

Under the Paperson Reduction Act at 1883, no partient or copulated to respond to a coloration of information unition is contain a well CMB control number

Substitute for form 1448A/PTO Complete If Known information disclosure Application Number 09/318,501 Filing Data March 3, 2000 Statement by applicant First Named Inventor Erlon et al. Group Art Unit 1824 (use as many sheets as necessary) Y. McKenzie Examinar Nama ATEM B of **Attorney Decket Rumber** 032485.00013.RCE (C(P1)

			non patent literature documents	
Enz tratti	mbror ets	Ctto No.	include nome of the quitter (in CAPITAL LETTERS), time of the critical (exten appropriate), title of the litem (been), magazina, journal, early, comparison, easing, oth), date, pagately, reducedous number(s), publisher, disy choice country chars published.	To
Sy.	レ	1	ernis and Bundgaard, "Prodrugs of Phosphates and Phosphonates: Novel Lipophilic o- acyloxyalkyl Ester Derivatives of Phosphate- or Phosphonate Containing Drugs Masking the Negative Charges of these Groups," <u>Euro, J. Pharm. Sci.</u> , 4:49-59 (1996).	
			Harada et al., "Resoluation of 1,3-alkanediols Via Chiral Spiroketals Derived from t- Menthone," <u>Tetrahedron</u> , 28(41):4843-4846 (1987).	
			Khorana et al., "Cyclic Phosphates. III. Some General Observations on the Formation and Properties of Five-, Six- and Seven-membered Cyclic Phophate Esters," <u>IACS</u> , 79:430-436 (1957).	
			Korba et al., "Liver-targeted Antiviral Nucleosides: Enhanced Antiviral Activity of Phosphatidyl-dideoxyguanosine Versus Dideoxyguanosine in Woodchuck Hepatitis Virus Infection In Vivo," Hepatology, 23(5):958-963 (1996).	
		,	Lefebvre et al., "Mononucleoside Phosphotriester Derivatives with S-acyl-2-thioethyl Bioreversible Phosphate-protecting Groups: Intracellular Delivery of 3'azido- 2',3'dideoxythymidine 5'-monophosphate," J. Med. Chem., 38:3941-3950 (1995).	
			Ludeman et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4.  Preparation, Kinetic Studies, and Anticancer Screening of "Phenylketophosphamide" and Similar Compounds Related to the Cyclophosphamide Metabolite Aldophosphamide," <u>J. Med.</u> Chem., 29:716-727 (1986).	
			McGuigan et al., "Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT," J. Med. Chem., 36:1048-1052 (1993).	
			Mosbo and Verkade, "Dipole Moment, Nuclear Magnetic Resonance, and Infrared Studies of Phosphorus Configurations and Equilibria in 2-R-2-Oxo-1,3,2-dioxaphosphorinanes," <u>J. Org. Chem.</u> , 42(9):1549-1555 (1977).	
			Nakayama and Thompson, "A Highly Enantioselective Synthesis of Phosphate Triesters," L Am. Chem. Soc., 112:6936-3942 (1990).	-
Y			Ramachandran et al., "Efficient General Synthesis of 1,2- and 1,3-diols in High Enantiomeric Excess via the Intramolecular Asymmetric Reduction of the Corresponding Ketoalkyl Diisopinocamphcylborinate Intermediates," <u>Tetrahedron</u> , 38(3):761-764 (1997).	

	J	 •		/ /	•
Examiner	1600 11	Date	1177	1 1	10
Signature /	March	Considered	9/1		<del>)</del>
( Y	~~~			<del>~~</del>	

"EXPLINER: INITIAL II retaronco considered, uncliner or not citation is in conformance with MPEP 600, Open line through distant is not in conformance and not considered. Include copy of this form with next conformance in applicant.

Burden Hour Statement: This farm is estimated to take 2.0 bours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this farm should be sent to the Chief information Officer, U.S. Petent and Trademark. Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Potents.

Washington, DC 20231.

<sup>\*</sup>Unique distinct designation number. \* Sees eleathed Kinds of U.S. Patent Decuments. \* Enter Office that braced the decument, by the tro-letter code (MIPO Standard ST.3). \* For Japanese patent documents, the indicates of the patent for only of the Emparer must precade the earth number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 10 II possible. \* Applicant is to place o check math hore if English Englishes Translation is situated.

PTO/SB/BBA (08-00)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Tredemark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COUNSERCE.

WORK Roduction Act of 1996, no persons are required to respond to a collection of information unitses & contains a valid OMB control number.

Sut	estitute for form 1449	APTO		Complete If Known			
JINE	ORMATION	DISCI	OSLIPE	Application Number	09/518,501		
<b>ST.</b>	TELELLY S	1		Filing Date	March 3, 2000		
<b>野!</b> /	TEMENT B	ST APP	LICANI	First Named Inventor	Erion et al.		
<b>y</b>				Group Art Unit	1624 ·		
(use as many sheets as necessary)				Examinar Name	T. McKenzie		
et	3	of	3	Attorney Docket Number	032465.00013.RCE (CIP1)		

		NON PATENT LITERATURE DOCUMENTS	_
Examiner tratiats	Cita No.1	Indude name of the super (in CAPITAL LETTERS), tile of the critic (when expropriate), tile of the florn (book, magazine, journel, acrisi, symposium, cotalog, cite.), date, page(s), volume-lasse member(s), publisher, city and/or country where published.	T
81		Starrett, Jr. et al., "Synthesis, Oral Bloavallability Determination, and <i>in Vitro</i> Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA)," <u>J. Med. Chem.</u> , 37:1857-1864 (1994).	
		Thomson et al., "Synthesis, Bioactivation and Anti-HIV Activity of the Bis(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Esters of the 5'-monophosphate of AZT," J. Chem. Soc., Perk. Trans. 1, (11):1239-1245 (1993).	
		Weber and Waxman, "Activation of the Anti-cancer Drug Ifosphamide by Rat Liver Microsomal P450 Enzymes," Biochem. Pharm., 45(8):1685-1694 (1993).	T
		Zon et al., "NMR Spectroscopic Studies of Intermediary Metabolites of Cyclophosphamide. A Comprehensive Kinetic Analysis of the Interconversion of cis- and trans-4- Hydroxycyclophosphamide with Aldophosphamide and Concomitant Partitioning of Aldophosphamide Between Irreversible Fragmentation and Reversible Conjugation Pathways," 1. Med. Chem. 27:466-485 (1984).	

Examiner Signature | On McClept | Date | 4/16/07

"EXAMPLER: Initial if returence considered, whether or not dilation is in conformance with MPEP 809. Draw one through distion is not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This term is estimated to take 2.0 hours to complete. Timo will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup> Unique distion designation number. \* See attached Kinds of U.S. Patent Documents. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must procede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. \* Applicant is to place a check mark here if English tanguage Transfellon is effected.

		/	13416	<del></del>			Page 1 of 3
			nm 2 8 2005 6	ATTY. DOCKET NO. -2358.0010002/RWE/C.	w o	PPLICATION NO. 9/518,501	rage 1 of 3
	•	DISCLOSURE	TON C. S.	FIRST NAMED INVENTO	R		
INFO	RMATION	DISCLOSURE	MIEMENT	FILING DATE		RT UNIT 624	
<u> </u>			U.S. PA	March 3, 2000 TENT DOCUMENTS		024	
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-ÇLASS	FILING DATE
a~	AA1	3,404,178	10/01/1968	Roy, C.H.		<i>[</i>	10/07/1965
1	AB1	4,621,077	11/04/1986	Rosini et al.			06/08/1984
	AC1	4,659,825	04/21/1987	Holy et al.			01/06/1984
	AD1	4,705,651	11/10/1987	Staibano			10/11/1985
	AE1	4,724,232	02/09/1988	Rideout et al.			09/17/1985
	AF1	4,724,233	02/09/1988	De Clercq et al.			04/21/1986
	AG1	4,777,163	10/11/1988	Bosies et al.			07/24/1987
	AH1	4,808,716	02/28/1989	Holy et al.			04/25/1986
	Al1	4,861,759	08/29/1989	Mitsuya et al.			08/11/1987
	AJ1	4,879,277	11/07/1989	Mitsuya et el.			08/11/1987 ·
	AK1	4,882,142	11/21/1989	Simon et al.			12/19/1988
			FOREIGN	PATENT DOCUMENTS	\$		
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No
	17.4	OTHER	Including Author	or, Title, Date, Pertiner	nt Pages, etc.	)	110
							•
	AR						••
							•
	AS						
	1				<del></del>		
	AT			•			ن ا ن
		10/1/				//	•••
EXAMINER	791	11/11 Ke	Per)		DATE	CONSIDERED	
EXAMINER: IA	Hal Wrese	inge considered, whe	ther or hot citation is	In conformance with MPEP 6	609. Draw line th	rough oftation if no	t in conformance

OIPE		
(1)		Page 2 of 3
JUH 2 8 2005 55	ATTY, DOCKET NO. 2358.0010002/RWE/CJW	APPLICATION NO. 09/518,501
INFORMATION DISCLOSURE STATEMENT	FIRST NAMED INVENTOR	
240.	Erion et al.	
INFORMATION DISCLOSURE STATEMENT	FILING DATE	ART UNIT
	March 3, 2000	1624

			U.S. I	PATENT DOCUMENTS	<b>S</b>		
EXAMINER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE:
INITIAL	AA2	4,898,724	02/06/1990	Simon et al.	CDAS	305-05-33	05/14/1987
-	AB2	4,939,130	07/03/1990	Jaeggi et el.			02/27/1989
	AC2	5,034,394	07/23/1991	Daluge			12/22/1989
	AD2	5,047,533	09/10/1991	Reist et al.			01/22/1990
	AE2	5,089,500	02/18/1992	Daluge			05/08/1991
	AF2	5,153,183	10/06/1992	Kawabe et al.			05/06/1991
	AG2	5,210,085	05/11/1993	Liotta et al.			02/22/1991
	AH2	5,240,946	08/31/1993	Kinney et al.			04/29/1992
	Al2	5,246,937	09/21/1993	Hamden et al.			01/22/1992
	AJ2	5,366,965	11/22/1994	Strein			01/29/1993
4	AK2	5,480,875	01/02/1996	Isomura et al.			371 Date: 12/21/1994
EVANUES		·	FOREIG	N PATENT DOCUME	NTS		-
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	АМ						Yes No
	AN	·					Yes No
	AO						Yes No
	AP						Yes No
	1	OTHER	(Including Au	thor, Title, Date, Perti	nent Pages, etc	.)	
	AR						ميو.
	AS						
	AT		· //				
EXAMINER	On,		En .		DATE	CONSTDERED	6
EXAMINER:	Initial If refer	ence considered who	ether or not citation	n is in conformance with MP	EP 609. Draw line th	rough distion if no	t in conformance

•	OIPE			
	(A)		Page 3 of 3	<u>;</u>
FORM PTO-1449		ATTY. DOCKET NO. 2358.0010002/RWE/CJW FIRST NAMED INVENTOR	APPLICATION NO. 09/518,501	_
INFORMATION DISCLOSURE	STA BOBY	Erion et al. FILING DATE March 3, 2000	ART UNIT 1624	_

					U.S	. PAT	ENT DOCUMEN	ITS					
EXAMIN	NER			JMENT			_			_			
INITIAL			NUME		DATE		NAME		CLAS	5	SUB-C	ÇASS	FILING DATE
/		AA3	5,532,	,225	07/02/1996	F	Reist et al.			Ĭ			07/31/1992
		AB3	5,583,	,122	12/10/1996	8	Benedict et al.						12/08/1985
		AC3	5,663,	,159	09/02/1997		Starrett, Jr. et al.						10/11/1994
		AD3	5,681,	,590	10/28/1997	E	Bechard et al.						371 Date: 07/26/1995
		AE3	5,721,	,219	02/24/1998	1	ngall <i>et al</i> .						08/09/1995
		AF3	5,814,	639	09/29/1998	ı	iotta et al.				1		02/16/1993
		AG3	5,840,	,716	11/24/1998	Ī	lbasawa et al.		1				01/17/1997
		AH3	5,869,	,467	02/09/1999	1	loly et al.		$\neg$				03/28/1995
0		Al3	5,914,	331	06/22/1999	Ī	iotta et el.		1				06/07/1995
		AJ					· ·				1		
		AK .											
					FOREI	IGN P	ATENT DOCUM	ENTS					<u></u>
EXAMIN INITIAL	IER			UMENT	DATE		COUNTRY		CLAS	s	SUB-CI	ASS	TRANSLATION"
	<	AL					)						Yes No
		AM									-		Yes No
		AN	1										Yes No
		AO					<del>-</del> ·· · · · · · · · · · · · · · · · · ·		1				Yes No
		AP							1				Yes No
		174		OTHER (	Including A	Author	r, Title, Date, Pe	rtinent P	ages,	etc.)			140
		AR											
		AS											: :
		AT .			10							/	 :
EXAMIN	1 1	5	, ,	Mc/			<u> </u>			7	POMSID	ヘファー	_
EXAMINE and not or	R: Initi	al II refer ed. Includ	erice obr	nsidered, whe	ther of not cital	tion is li inicatio	n conformance with I n to Applicant	MPEP 609.	Oraw lin	e thre	ugh cata	on if not	in conformance

403868\_3.DOC

SKGF Rev. 12/03/03



Sheet '	1 of	12
---------	------	----

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

#### **U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Document Number	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant	Relevant Pages
-teu	A1	3,796,700	03/12/1974	Yoshioka et al.	all
	A2	4,255,566	03/10/1981	Carrico et al.	all
	A3	4,318,982	03/09/1982	Homby et al.	all
	A4	4,340,668	07/20/1982	Hornby et al.	all
	A5	4,376,165	03/08/1983	Hornby et al.	all
	A6	4,447,529	05/08/1984	Greenquist et al.	all
	A7	4,804,655	02/14/1989	Müller et al.	all
	A8	5,204,355	04/20/1993	Zsadon et al.	all
	A9	5,212,304	05/18/1993	Fung et al.	all
	A10	5,258,538	11/02/1993	Fung et al.	all
	A11	6,117,873	09/12/2000	Acklin et al.	all
./	A12	6,752,981 B1	06/22/2004	Erion et al.	all
W	A13	6,756,360 B1	06/29/2004	Erion et al.	all

#### **FOREIGN PATENT DOCUMENTS**

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.	Document (Cty code-number-kind)	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant	Relevant Pages	T,			
47	B1	WO 91/19721 A1	12/26/1991	Glazier, Arnold	all				
17	B2	WO 97/22614 A1	06/26/1997	Chiroscience Ltd.	all				
L	B3	WO 01/39724 A2	06/07/2001	Regents of Univ. of Calif.	all				
					all				

Examiner Signature On Market	Date Considered 3/11/06

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant is to place a check mark here if English language translation is attached.

Sheet 2 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

Examiner	Cite		T
Initials*	No.	Description	
	C1	ALARCON, R.A., "Studies on the In Vivo Formation of Acrolein: 3-Hydroxy-	
1 art		propylmercapturic Acid as an Index of Cyclophosphamide (NSC-26271) Activation,"	
1 17	٦'	Cancer Treatment Reports 60(4), 327-335, U.S. National Cancer Institute (1976).	
7	C2	ALEXANDER, P. et al., "Preparation of 9-(2-Phosphonomethoxyethyl) Adenine Esters as	
1 1		Potential Prodrugs," Collect. Czech. Chem. Commun. 59, 1853-1869, Nakladatelstvi	
1 1		Ceskoslovenski Akademie Ved. (1994).	
	C3	AMIN, D. et al., "1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic Acid as	
1 1		a Potent Inhibitor of Squalene Synthase," ArzneimForsch/Drug Res. 46(8), 759-762,	
		Editio Cantor (1996).	
	C4	ANDERSON, L.W. et al., "Cyclophosphamide and 4-Hydroxycyclophosphamide/	
1 [		Aldophosphamide Kinetics in Patients Receiving High-Dose Cyclophosphamide	
		Chemotherapy," Clinical Cancer Research 2, 1481-1487, American Association for	
1 1		Cancer Research (1996).	
	C5	ANNAERT, P. et al., "Transport, Uptake, and Metabolism of the Bis(pivaloyloxymethyl)-	
		Ester Prodrug of 9-(2-Phosphonylmethoxyethyl) Adenine in an In Vitro Cell Culture	
1 1	1	System of the Intestinal Mucosa (Caco-2)," Pharm. Res. 14(4), 492-496, Plenum	
		Publishing Corporation (1997).	
	C6	ATIQ, O.T. et al., "Treatment of Unresectable Primary Liver Cancer with Intrahepatic	
1 1		Fluorodeoxyuridine and Mitomycin C Through an Implantable Pump," Cancer 69(4), 920-	
		924, American Cancer Society (1992).	
	C7	AUBERSON, Y.P. et al., "N-Phosphonoalkyl-5-Aminomethylquinoxaline-2,3-Diones: In	
}		Vivo Active AMPA and NMDA-(Glycine) Antagonists," Bioorg. Med. Chem. Lett. 9, 249-	
		254, Elsevier Science Ltd. (January 1999).	
	C8	BAKER, M.A. et al., "Microtiter Plate Assay for the Measurement of Glutathione and	
	]	Glutathione Disulfide in Large Numbers of Biological Samples," Anal. Biochem. 190, 360-	
11	1	365, Academic Press, Inc. (1990).	
	C9	BALTHAZOR, T.M. et al., "Nickel-Catalyzed Arbuzov Reaction: Mechanistic	
		Observations," J. Org. Chem. 45, 5425-5426, American Chemical Society (1980).	
	C10	BEDFORD, S.B. et al., "Synthesis of Water-Soluble Prodrugs of the Cytotoxic Agent	
	_	Combretastatin A4," Bioorg. Med. Chem. Lett. 6(2), 157-160, Elsevier Science Ltd.	
	+	(1996).	

		~		NC.				/	
Examiner Signature	1	10n	Wel	Je	Date Considered	3/	///	06	
		7	(	7			7		

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant is to place a check mark here if English language translation is attached.

Sheet 3 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

Examiner	Cite		T
Initials* No.		Description	
Jer C11 B		Beilstein Registry Number 3635189, Beilstein Institut zur Foerderung der Chemischen Wissenschaften (1991).	
	C12	BENTRUDE, W.G. et al., "Stereo- and Regiochemistries of the Oxidations of 2-Methoxy-5-tert-butyl-1,3,2-dioxaphosphorinanes and the Cyclic Methyl 3'5'-Phosphite of Thymidine by H <sub>2</sub> O/l <sub>2</sub> and O <sub>2</sub> /AIBN to P-Chiral Phosphates. <sup>17</sup> O NMR Assignment of Phosphorus Configuration to the Diasteromeric Thymidine Cyclic Methyl 3'5'-Monophosphates," <i>J. Am. Chem. Soc.</i> 111, 3981-3987, American Chemical Society (1989).	
	C13	BERRY, M.N. et al., "High-Yield Preparation of Isolated Rat Liver Parenchymal Cells," J. of Cell Biology 43, 506-520, Rockefeller University Press (1969).	
	C14	BESPALOV, A. et al., "Prolongation of Morphine Analgesia by Competitive NMDA Receptor Antagonist D-CPPene (SDZ EAA 494) in Rats," <i>Eur. J. Pharmacol.</i> 351, 299-305, Elsevier Science B.V. (June 1998).	
	C15	BIJSTERBOSCH, M.K. et al., "Disposition of the Acyclic Nucleoside Phosphonate (S)-9-(3-Hydroxy-2-Phosphonylmethoxyproply)Adenine," <i>Antimicrobial Agents and Chemotherapy</i> 42, 1146-1150, American Society for Microbiology (May 1998).	
	C16	BIRD, J. et al., "Synthesis of Novel N-Phosphonoalkyl Dipeptide Inhibitors of Human Collagenase," J. Med. Chem. 37, 158-169, American Chemical Society (1994).	
	C17	BODDY, A.V. et al., "Individual Variation in the Activation and Inactivation of Metabolic Pathways of Cyclophosphamide," <i>J. National Cancer Institute</i> 84(22), 744-748, Oxford University Press (1992).	
	C18	BORCH, R.F. et al., "Synthesis, Activation and Cytotoxicity of Aldophosphamide Analogues," J. Med. Chem. 34, 3052-3058, American Chemical Society (1991).	
	C19	BORCH, R.F. et al., "Synthesis and Antitumor Properties of Activated Cyclophosphamide Analogues," J. Med. Chem. 34, 3044-3052, American Chemical Society (1991).	
	C20	BOYD, V.L. et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 3. Preparation, Molecular Structure Determination, and Anticancer Screening of Racemic cis- and trans-4-Phenylcyclophosphamide," J. Med. Chem. 23, 372-375, American Chemical Society (1980).	
d	C21	BRAIN, E.G.C. et al., "Modulation of P450-Dependent Ifosfamide Pharmacokinetics: a Better Understanding of Drug Activation In Vivo," <i>British J. of Cancer</i> 77(11), 1768-1776, Cancer Research Campaign (June 1998).	

	<u> </u>				
Examiner	Don M	101/2	Date -	2/, /	
Signature	/ Vem II	clhr _	Considered 5	5/W/	04
		7		7 7 -	

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant is to place a check mark here if English language translation is attached.

Sheet 4 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

### NON PATENT LITERATURE DOCUMENTS

Examiner	Cite		T
Initials*	No.	Description	
Th	C22	BRENNA, O. et al., "Affinity-Chromatography Purification of Alkaline Phosphatase from Calf Intestine," <i>Biochem. J.</i> 151, 291-296, Portland Press on behalf of The Biochemical Society (1975).	
	C23	BRILL, T.B. et al., "Arbuzov-like Dealkylation Reactions of Transition-Metal-Phosphite Complexes," Chem. Rev. 84, 577-585, American Chemical Society (1984).	
	C24	BROCK, N. et al., "Acrolein, the Causative Factor of Urotoxic Side-effects of Cyclophosphamide, Ifosfamide, Trofosfamide and Sufosfamide" <i>Arzneimittel Forschung Drug Research</i> 29(4), 659-661, Editio Cantor (1979).	
	C25	CAMPAGNE, JM. et al., "Synthesis of Mixed Phosphonate Diester Analogues of Dipeptides using BOP or PyBOP Reagents," <i>Tetrahedron Lett.</i> 34(42), 6743-6744, Pergamon Press Ltd. (1993).	
	C26	CAMPBELL, D.A., "The Synthesis of Phosphonate Esters, an Extension of the Mitsunobu Reaction," <i>J. Org. Chem.</i> 57, 6331-6335, American Chemical Society (1992).	
	C27	CASARA, P.J. et al., "Synthesis of Acid Stable 5'-O-Fluoromethyl Phosphonates of Nucleosides. Evaluation as Inhibitors of Reverse Transcriptase," <i>Bioorg. Med. Chem. Lett.</i> 2(2), 145-148, Pergamon Press plc. (1992).	
	C28	CASTEEL, D.A. et al., "Steric and Electronic Effects in the Aryl Phosphate to Arylphosphonate Rearrangement," <i>Synthesis</i> , 691-693, Sendai Institute of Heterocyclic Chemistry (1991).	
	C29	CHANG, T.K.H. et al., "Enhanced Cyclophosphamide and Ifosfamide Activation in Primary Human Hepatocyte Cultures: Response to Cytochrome P-450 Inducers and Autoinduction by Oxazaphosphorines," Cancer Research 57, 1946-1954, American Association for Cancer Research (1997).	
	C30	CHEN, L. et al., "Intratumoral Activation and Enhanced Chemotherapeutic Effect of Oxazaphosphorines following Cytochrome P-450 Gene Transfer: Development of a Combined Chemotherapy/Cancer Gene Therapy Strategy," Cancer Research 55, 581-589, American Association for Cancer Research (1995).	
	C31	CHEN, L. et al., "Sensitization of Human Breast Cancer Cells to Cyclophosphamide and Ifosfamide by Transfer of a Liver Cytochrome P450 Gene," <i>Cancer Research</i> 56, 1331-1340, American Association for Cancer Research (1996).	
1	C32	CLARK, L. et al., "Oxidative Metabolism of Cyclophosphamide: Identification of the Hepatic Monooxygenase Catalysts of Drug Activation," Cancer Research 49, 2344-2350 American Association for Cancer Research (1989).	

	// · · · · · · · · · · · · · · · · · ·		
Examiner Signature Dom Mc/	Sia	Date Considered	/11/06

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant is to place a check mark here if English language translation is attached.

Sheet 5 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

Examine	er Cite		T
Initials*	No.	Description	
~^^	C33	DAVIS, L. et al., "Effect of Withania somnifera on Cyclosphosphamide-induced	
gr	`	Urotoxicity," Cancer Letters 148, 9-17, Elsevier Science Ireland Ltd. (January 2000).	
	C34	DEARFIELD, K.L. et al., "Analysis of the Genotoxicity of Nine Acrylate/Methacrylate Compounds in L5178Y Mouse Lymphoma Cells," <i>Mutagenesis</i> 4, 381-393, IRL Press,	
$\vdash$	1005	Oxford (1989).	<del> </del>
	C35	DELEVE, L.D. et al., "Cellular Target of Cyclophosphamide Toxicity in the Murine Liver: Role of Glutathione and Site of Metabolic Activation," <i>Hepatology</i> 24(4), 830-837, American Association for the Study of Liver Diseases (1996).	
	C36	DELOMBAERT, S. et al., "Pharmacological Profile of a Non-Peptidic Dual Inhibitor of Neutral Endopeptidase 24.11 and Endothelin-Converting Enzyme," <i>Biochem. Biophys. Res. Commun.</i> 204(1), 407-412, Academic Press, Inc. (1994).	
	C37	DESOS, P. et al., "Structure-Activity Relationships in a Series of 2(1H)-Quinolones Bearing Different Acidic Function in the 3-Position: 6,7-Dichloro-2(1H)-oxoquinoline-3-phosphonic Acid, a New Potent and Selective AMPA/Kainate Antagonist with Neuroprotective Properties," J. Med. Chem. 39, 197-206, American Chemical Society (1996).	
	C38	DICKSON, J.K. et al., "Orally Active Squalene Synthase Inhibitors: Bis((acyloxy)alkyl) Prodrugs of the α-Phosphonosulfonic Acid Moiety," <i>J. Med. Chem.</i> 39, 661-664, American Chemical Society (1996).	
	C39	ENRIQUEZ, P.M. et al., "Conjugation of Adenine Arabinoside 5'-Monophosphate to Arabinogalactan: Synthesis, Characterization, and Antiviral Activity," <i>Bioconjugate Chem.</i> 6, 195-202, American Chemical Society (1995).	
	C40	ERION, M.D. et al., "Design, Synthesis, and Characterization of a Series of Cytochrome P <sub>450</sub> 3A-Activated Prodrugs (HepDirect Prodrugs) Useful for Targeting Phosph(on)ate-Based Drugs to the Liver," <i>J. Am. Chem. Soc.</i> 126, 5154-5163, American Chemical Society (April 2004).	
	C41	ERION, M.D. et al., "Liver-Targeted Drug Delivery Using HepDirect Prodrugs," <i>J. of Pharmacology &amp; Experimental Therapeutics</i> 312(2), 554-560, The American Society for Pharmacology and Experimental Therapeutics (February 2005).	
0	C42	FARQUHAR, D. et al., "Biologically-Cleavable Phosphate Protective Groups: 4-Acyloxy-1,3,2-Dioxaphosphorinanes as Neutral Latent Precursors of Dianionic Phosphates," <i>Tetrahedron Lett.</i> 36(5), 655-658, Elsevier Science Ltd. (1995).	

Examiner	7	7~		Wa	17	22	Date	7	7		• /	
Signature	$\Delta \Delta$	10pm			/ 4	0	Considered	1/	Il		90	
			, ,		7			_	,	/		

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant is to place a check mark here if English language translation is attached.

Sheet 6 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

#### **NON PATENT LITERATURE DOCUMENTS**

Exam	iner	Cite		T				
Initial	s*	No.	Description					
		C43	FIUME, L. et al., "Inhibition of Hepatitis B Virus Replication by Vidarbine Monophosphate					
gru		1	Conjugated with Lactosaminated Serum Albumin," The Lancet 13-15, Lancet Publishing					
1			Group (1988).					
	1	C44	FRAISER, L. et al., "Murine Strain Differences in Metabolism and Bladder Toxicity of					
			Cyclophosphamide," Toxicology 75, 257-272, Elsevier Scientific Publishers (1992).					
	I - I	C45	GAO, Y. et al., "Asymmetric Synthesis of Both Enantiomers of Tomoxetine and					
			Fluoxetine. Selective Reduction of 2,3-Epoxycinnamyl Alcohol with Red-A1," J. Org.					
<u> </u>			Chem. 53, 4081-4084, American Chemical Society (1988).					
		C46	GILARD, V. et al., "Chemical Stability and Fate of the Cytostatic Drug Ifosfamide and Its	1				
			N-Dechloroethylated Metabolities in Acidic Aqueous Solutions," J. Med. Chem. 42, 2542-	İ				
			2560, American Chemical Society (July 1999).					
j	1	C47	GROEN, A.K. et al., "Intracellular Compartmentation and Control of Alanine Metabolism	ŀ				
			in Rat Liver Parenchymal Cells," Eur. J. Biochem. 122, 87-93, FEBS (1982).					
1 1		C48	GUIDA, W.C. et al., "Structure-Based Design of Inhibitors of Purine Nucleoside	ł				
1 1			Phosphorylase. 4. A Study of Phosphate Mimics," J. Med. Chem. 37, 1109-1114,	}				
			American Chemical Society (1994).	ļ				
1		C49	GURTOO, H.L. et al., "Role of Glutathione in the Metabolism-dependent Toxicity and					
1	.		Chemotherapy of Cyclophosphamide," Cancer Research 41, 3584-3591, American	1				
			Association for Cancer Research (1981).	ļ				
1 1		C50	GUSTIN, N.C. et al., "A Rapid, Sensitive Assay for Adenosine Deaminase," Analytical	i				
			Biochemistry 71, 527-532, Academic Press, Inc. (1976).					
l' \		C51	HAYAKAWA, Y. et al., "Benzimidazolium Triflate as an Efficient Promoter for Nucleotide	ļ				
	l		Synthesis via the Phosphoramidite Method," J. Org. Chem. 61, 7996-7997, American					
			Chemical Society (1996).					
		C52	HILTON, J., "Role of Aldehyde Dehydrogenase in Cyclophosphamide-resistant L1210					
			Leukemia," Cancer Research 44, 5156-5160, American Association for Cancer Research					
			(1984).					
_]	,	C53	HIRAYAMA, N. et al., "Structure and Conformation of a Novel Inhibitor of Angiotensin I					
<i>()</i> {	<b>/</b>		Converting Enzyme - a Tripeptide Containing Phosphonic Acid," Int. J. Pept. Protein Res.					
			38, 20-24, Munksgaard International Publishers (1991).					

					<i></i>
Examiner		111 //(0 -	Date	1/1/	5 (
Signature	10m	11/1/40	Considered	3/11/	٨ ا

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant is to place a check mark here if English language translation is attached.

Sheet 7 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

### NON PATENT LITERATURE DOCUMENTS

Examiner	Cite		T
Initials*	No.	Description	
gr	C54	JOUNAIDI, Y. et al., "Frequent, Moderate-Dose Cyclophosphamide Administration Improves the Efficacy of Cytochrome P-450/Cytochrome P-450 Reductase-based Cancer Gene Therapy," Cancer Research 61, 4437-4444, American Association for Cancer Research (June 2001).	
	C55	KACHEL, D.L. et al., "Cyclophosphamide-Induced Lung Toxicity: Mechanism of Endothelial Cell Injury," <i>J. Pharmacology and Experimental Therapeutics</i> 268(1), 42-46, The American Society for Pharmacology and Experimental Therapeutics (1994).	
	C56	KEENAN, R.E. et al., "Pathology Reevaluation of the Kociba et al. (1978) Bioassay of 2,3,7,8-TCDD: Implications for Risk Assessment," <i>J. Tox. Envir. Health</i> 34, 279-296, Hemisphere Publishing Corporation (1991).	
	C57	KELLEY, J.L. et al., "[[(Guaninylalkyl)phosphinico] methyl] phosphonic Acids. Multisubstrate Analogue Inhibitors of Human Erythrocyte Purine Nucleoside Phosphorylase," J. Med. Chem. 38, 1005-1014, American Chemical Society (1995).	
	C58	KHAMNEI, S. et al., "Neighboring Group Catalysis in the Design of Nucleotide Prodrugs," J. Med. Chem. 39, 4109-4115, American Chemical Society (1996).	
	C59	KURIYAMA, S. et al., "Transient Cyclophosphamide Treatment Before Intraportal Readministration of an Adenoviral Vector can Induce Re-expression of the Original Gene Construct in Rat Liver," <i>Gene Therapy</i> 6, 749-757, Stockton Press (May 1999).	
	C60	KWON, CH. et al., "Effects of N-Substitution on the Activation Mechanisms of 4- Hydroxycyclophosphamide Analogues," <i>J. Med. Chem.</i> 32, 1491-1496, American Chemical Society (1989).	
	C61	LILO, B. et al., "Synthesis and Configurational Assignment of Bicyclic 'Preactivated' Analogues of Cyclophosphamide," <i>Tetrahedron Letters</i> 31(6), 887-890, Pergamon Press plc. (1990).	
	C62	LOW, J.E. et al., "Conversion of 4-Hydroperoxycyclophosphamide and 4- Hydroxycyclophosphamide to Phosphoramide Mustard and Acrolein Mediated by Bifunctional Catalysts," <i>Cancer Research</i> 42, 830-837, American Association for Cancer Research (1982).	
	C63	LU, X. et al., "Palladium-Catalyzed Reaction of Aryl Polyfluoroalkanesulfonates with O,O-Dialkyl Phosphonates," Synthesis 726-727, Academic Press (1987).	
0	C64	LUDEMAN, S.M. et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogs.  1. Benzo Annulated Cyclophosphamide and Related Systems," <i>J. Med. Chem.</i> 18(12),  1251-1253, American Chemical Society (1975).	

Examiner Date Considered 3/1/06			//	
	Examiner	1/1/	Date	2//
Orginature / 1 / 1/01/2011 / 1/01/2011 / 1/01/2011 / 1/01/2011 / 1/01/2011	Signature	On Well	Considered	13/4/06

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant is to place a check mark here if English language translation is attached.

Sheet 8 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

Examiner	Cite		TT
Initials*	No.	Description	'
Hillais	C65	LUDEMAN, S.M. et al., "Synthesis and Antitumor Activity of Cyclophosphamide	<del>                                     </del>
	000	Analogues. 2. Preparation, Hydrolytic Studies, and Anticancer Screening of 5-	
lan.		Bromocyclophosphamide, 3,5-Dehydrocyclophosphamide, and Related Systems," <i>J.</i>	
		Med. Chem. 22(2), 151-158, American Chemical Society (1979).	1
<del></del>	C66	LUDEMAN, S.M. et al., "Synthesis of Reactive Metabolite-Analogues of	<del>                                     </del>
/	000	Cyclophosphamide for Comparisons of NMR Kinetic Parameters and Anticancer	
1 (		Screening Data," <i>Drugs Exptl. Clin. Res.</i> XII 6/7, 527-532, Bioscience Ediprint Inc. (1986).	
<del>   </del>	C67	MAY-MANKE, A. et al., "Investigation of the Major Human Hepatic Cytochrome P450	<del> </del>
	1007	Involved in 4-Hydroxylation and N-dechloroethylation of Trofosfamide," Cancer	
1 1		Chemother. Pharmacol. 44, 327-334, Springer-Verlag (August 1999).	
<del>                                     </del>	C68	MAYNARD-FAURE, P. et al., "New Strategy for the Diastereoselective Synthesis of	-
	C00	Bicyclic 'Pre-activated' Analogues of Cyclophosphamide," <i>Tetrahedron Letters</i> 39, 2315-	
1 1	1	2318, Elsevier Science Ltd. (April 1998).	1
	C69	MCGUIGAN, C. et al., "Kinase Bypass: A New Strategy for Anti-HIV Drug Design,"	
	Cos	Bioorganic & Medicinal Chemistry Letters 3(6): 1207-1210, Pergamon Press Ltd. (1993).	
<del></del>	C70	MEIER, C. et al., "ADA-Bypass by lipophilic Cyclo-Sal-ddAMP Pro-Nucleotides A second	
	070	Example of the Efficiency of the cycloSat-Concept," Bioorg. Med. Chem. Lett. 7(12),	1
		1577-1582, Elsevier Science Ltd. (1997).	
<del></del>	C71	MEIER, C. et al., "Cyclic Saligenyl Phosphotriesters of 2',3'-Dideoxy-2',3'-	<del> </del>
[	671	didehydrothymidine (d4T) – A New Pro-Nucleotide Approach," <i>Bioorganic Med. Chem.</i>	1
		Lett. 7(2), 99-104, Elsevier Science Ltd. (1997).	
<del></del>	C72	MEIJER, D.K.F. et al., "Covalent and Noncovalent Protein Binding of Drugs: Implications	<del>                                     </del>
1 1	012	for Hepatic Clearance, Storage, and Cell-Specific Drug Delivery," <i>Pharm. Res.</i> 6(2), 105-	
	l	118, Plenum Publishing Corporation (1989).	
<del></del>	C73	MELVIN, L.S., "An Efficient Synthesis of 2-Hydroxyphenylphosphonates," <i>Tetrahedron</i>	<del>                                     </del>
	0,3	Lett. 22(35), 3375-3376, Pergamon Press Ltd. (1981).	
<del></del>	C74	MISIURA, K. et al., "Synthesis and Antitumor Activity of Analogues of Ifosfamide Modified	<del> </del>
1 /	~, ~	in the N-(2-Chloroethyl) Group," <i>J. Med. Chem.</i> 31(1), 226-230, American Chemical	
1		Society (1988).	
<del> </del>	C75	MITCHELL, A.G. et al., "Bioreversible Protection for the Phospho Group: Bioactivation of	<del>                                     </del>
1 /	3,0	the Di(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Phosphoesters of	
		Methylphosphonate and Phosphonacetate," J. Chem. Soc. Perkin Trans. 1, 2345-2353,	
1 4r		Chemical Society, London (1992).	
L		Chomos court, some (100c)	L

Examiner Signature	Ton	Me 91.	Date Considered	3/11/06
		<i>//</i>		

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant is to place a check mark here if English language translation is attached.

Sheet 9 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

#### **NON PATENT LITERATURE DOCUMENTS**

Examiner	Cite		7
Initials*	No.	Description	'
IIIIIIais	C76	MITCHELL, J.R. et al., "Acetaminophen-Induced Hepatic Necrosis. IV. Protective Role of	
010	070	Glutathione," J. Pharmacology and Experimental Therapeutics 187(1), 211-217, The	
1	ŀ	Williams & Wilkins Co. (1973).	
<del>                                     </del>	C77	MITSUNOBU, O., "The Use of Diethyl Azodicarboxylate and Triphenylphosphine in	<del> </del>
/	011	Synthesis and Transformation of Natural Products," Synthesis 1-28, Georg Thieme	
		Verlag (1981).	
<del>   </del>	C78	MOORE, M.M. et al., "Comparison of Mutagenicity Results for Nine Compounds	<del> </del>
	078	Evaluated at the <i>hgprt</i> Locus in the Standard and Suspension CHO Assays,"	
		Mutagenesis 6, 77-85, Oxford University Press (1991).	
<del></del>	C79	MURRAY, G.I. et al., "Cytochrome P450 CYP3A in Human Renal Cell Cancer," <i>British</i>	
	0/9	Journal of Cancer 79, 1836-1842, Cancer Research Campaign (April 1999).	
	C80	MURRAY, G.I. et al., "Cytochrome P450 Expression is a Common Molecular Event in	<del>                                     </del>
	Cou	Soft Tissue Sarcomas," J. Pathology 171: 49-52, John Wiley & Sons, Ltd. (1993).	1
<del></del>	C04	NAGAMATSU, T. et al., "New Phosphorylating Agents for General Synthesis of Mixed	<del> </del>
	C81	Phosphate Esters," <i>Tetrahedron Lett.</i> 28(21), 2375-2378, Pergamon Journals Ltd. (1987).	
<del></del>	000	NAKAYAMA, K. et al., "A Highly Enantioselective Synthesis of Phosphate Triesters," J.	├──
\	C82		1
<del></del>	000	Am. Chem. Soc. 112, 6936-6942, American Chemical Society (1990).	┼
l \	C83	OGG, M.S. et al., "A Reporter Gene Assay to Assess the Molecular Mechanisms of	
\	1	Xenobiotic-dependent Induction of the Human CYP3A4 Gene in Vitro," Xenobiotica 29(3),	
<del></del>	004	269-279, Taylor & Francis Ltd. (March 1999).  OHASHI, K. et al., "Synthesis of Phosphonosphingoglycolipid Found in Marine Snail	╅
	C84		1
	005	Turbo Cornutus," Tetrahedron Lett. 29(10), 1189-1192, Pergamon Press plc. (1988).	-
	C85	PETRAKIS, K.S. et al., "Palladium-Catalyzed Substitutions of Triflates Derived from	
1	1	Tyrosine-Containing Peptides and Simpler Hydroxyarenes Forming 4-	
		(Diethoxyphosphinyl)phenylalanines and Diethyl Arylphosphonates," J. Am. Chem. Soc.	
-	000	109, 2831-2833, American Chemical Society (1987).	+
	C86	PETTIT, G.R. et al., "Antineoplastic Agents 322. Synthesis of Combretastatin A-4 Prodrugs," <i>Anti-Cancer Drug Design</i> 10, 299-309, Oxford University Press (1995).	
	C07	PITCHER, H.R., "Built-in Bypass," <i>Nature</i> 429, 39, Nature Publishing Group (May 2004).	+
	C87		
) ()	C88	RAMU, K. et al., "Acrolein Mercapturates: Synthesis, Characterization, and Assessment	
1 4	1	of Their Role in the Bladder Toxicity of Cyclophosphamide," Chem. Res. Toxicol. 8, 515-	l
		524, American Chemical Society (1995).	L

		1 4 1	/			
Examiner		1/1/1. /	7	Date	2//	
Signature/	Kon	11/10/	Si	Considered	7/11/06	
			/ 10			

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant is to place a check mark here if English language translation is attached.

Sheet 10 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

#### NON PATENT LITERATURE DOCUMENTS

		HON FATERI ETTERATORE DOCUMENTS			
Examiner	Cite	December 1997	T		
Initials*	No.	Description	<u> </u>		
_	C89	REDDY, M.R. et al., "Development of a Quantum Mechanics-Based Free-Energy			
g/2		Perturbation Method: Use in the Calculation of Relative Solvation Free Energies," J. Am.			
<del>'/</del>	C90	Chem. Soc. 126, 6224-6225, American Chemical Society (May 2004).			
1 /	C90	REDMORE, D., "Phosphorus Derivatives of Nitrogen Heterocycles. 2.			
		Pyridinephosphonic Acid Derivatives," J. Org. Chem. 35(12), 4114-4117, American Chemical Society (1970).			
	C91	REN, S. et al., "Inhibition of Human Aldehyde Dehydrogenase 1 by the 4-			
	Cal	Hydroxycyclophosphamide Degradation Product Acrolein," Drug Metabolism and			
[		Disposition 27(1), 133-137, The American Society for Pharmacology and Experimental			
.		Therapeutics (January 1999).			
<del></del>	C92	REN, S. et al., "Pharmacokinetics of Cyclophosphamide and its Metabolites in Bone			
	002	Marrow Transplantation Patients," Clinical Pharmacology and Therapeutics 64(3), 289-			
		301, Mosby, Inc. (September 1998).			
	C93	ROY, P. et al., "Development of a Substrate-Activity Based Approach to Identify the			
		Major Human Liver P-450 Catalysts of Cyclophosphamide and Ifosfamide Activation			
		Based on cDNA-Expressed Activities and Liver Microsomal P-450 Profiles," Drug			
		Metabolism and Disposition 27(6), 655-666, The American Society for Pharmacology and			
	Experimental Therapeutics (June 1999).				
	C94	SCHWARTZ, P.S. et al., "Cyclophosphamide Induces Caspase 9-Dependent Apoptosis			
		in 9L Tumor Cells," Molecular Pharmacology 60(6), 1268-1279, The American Society for			
		Pharmacology and Experimental Therapeutics (December 2001).			
	C95	SHIH, YE. et al., "Studies on Potential Antitumor Agents (III). Synthesis of 4-			
		Arylcyclophosphamides," Heterocycles 9 (9): 1277-1285, Sendai Institute of Heterocyclic			
		Chemistry (1978).			
	C96	SHIH, YE. et al., "Synthesis and Structure of 6-Phenylcyclophosphamides,"			
	007	Heterocycles 24(6), 1599-1603, Sendai Institute of Heterocyclic Chemistry (1986).	ļ		
İ	C97	SLADEK, N.E. et al., "Influence of Diuretics on Urinary General Base Catalytic Activity			
		and Cyclophosphamide-Induced Bladder Toxicity," Cancer Treatment Reports 66(11),			
	C98	1889-1900, U.S. National Cancer Institute (1982).  SLADEK, N.E. et al., "Restoration of Sensitivity to Oxazaphosphorines by Inhibitors of	<del> </del>		
	030		1		
	Aldehyde Dehydrogenase Activity in Cultured Oxazaphosphorine-resistant L1210 and Cross-Linking Agent-resistant P388 Cell Lines," Cancer Research 45, 1549-1555,				
1		American Association for Cancer Research (1985).			
<del></del>	C99	SPRINGATE, J. et al., "Toxicity of Ifosfamide and Its Metabolite Chloroacetaldehyde in			
		Cultured Renal Tubule Cells," In Vitro Cell Dev. BiolAnimal 35, 314-317, Society for In			
W/		Vitro Biology (June 1999).			
Examine		Date 2 /. /			
Signature	$\sim$ $\times$	Considered 5/11/06			
		100000000000000000000000000000000000000			

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant is to place a check mark here if English language translation is attached.

Sheet 11 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

Examiner	Cite		TT
Initials*	No.	Description	
977	C100	SUMIDA, A. et al., "Quantitative Analysis of Constitutive and Inducible CYPs mRNA Expression in the HepG2 Cell Line Using Reverse Transcription-Competitive PCR," Biochem. & Biophys. Res. Comm. 267, 756-760, Academic Press (January 2000).	
	C101	TURNER, J.A., "A General Approach to the Synthesis of 1,6-,1,7-, and 1,8-Naphthyridines," J. Org. Chem. 55(15), 4744-4750, American Chemical Society (1990).	
	C102	VENOOK, A.P., "Treatment of Hepatocellular Carcinoma: Too Many Options?," J. Clin. Oncol. 12(6), 1323-1334, Lippincott Williams & Wilkins (1994).	
	C103	VO-QUANG, Y. et al., "(1-Amino-2-propenyl)phosphonic Acid, an Inhibitor of Alanine Racemase and D-Alanine:D-Alanine Ligase," <i>J. Med. Chem.</i> 29(4), 579-581, American Chemical Society (1986).	
	C104	WAGNER, A. et al., "Direct Conversion of Tetrahydropyranylated Alcohols to the Corresponding Bromides," <i>Tetrahedron Letters</i> 30(5), 557-558, Pergamon Press plc. (1989).	
	C105	WALLACE, E.M. et al., "Design and Synthesis of Potent, Selective Inhibitors of Endothelin-Converting Enzyme," <i>J. Med. Chem.</i> 41, 1513-1523, American Chemical Society (April 1998).	
	C106	WALSH, E.N. et al., "Phenoxymethylphosphonic Acids and Phosphonic Acid Ion- exchange Resins," <i>J. Am. Chem. Soc.</i> 78, 4455-4458, American Chemical Society (1956).	
	C107	WATANABE, Y. et al., "Dibenzyl Phosphorofluoridate, A New Phosphorylating Agent," Tetrahedron Letters 29(45), 5763-5764, Pergamon Press plc. (1988).	
	C108	WATKINS, P.B., "Noninvasive Tests of CYP3A Enzymes," <i>Pharmacogenetics</i> 4, 171-184, Chapman & Hall, London (1994).	
	C109	WEIBEL, M. et al., "Potentiating Effect of {2-[2-[(2-Amino-1,6-Dihydro-6-Oxo-9H-Purin-9-yl)Methyl]-Phenyl] Ethenyl}-Phosphonic Acid (MDL 74,428), A Potent Inhibitor of Purine Nucleoside Phosphorylase, on the Antiretroviral Activities of 2',3'-Dideoxyinosine Combined to Ribavirin in Mice," <i>Biochem. Pharmacol.</i> 48(2), 245-252, Elsevier Science Ltd. (1994).	
	C110	WEINHARDT, K. et al., "Synthesis and Antidepressant Profiles of Phenyl-Substituted 2-Amino- and 2-[(Alkoxycarbonyl)amino]-1,4,5,6-tetrahydropyrimidines," <i>J. Med Chem.</i> 28, 694-698, American Chemical Society (1985).	
4	C111	WILEMAN, T. et al., "Receptor-Mediated Endocytosis," <i>Biochem. J.</i> 232: 1-14, Portland Press on behalf of the Biochemical Society, London (1985).	

		_4	4	<u> </u>			
Examiner Signature	$\mathbb{Z}$			Date Considered	3/	1/6	56
			77				

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant is to place a check mark here if English language translation is attached.

Sheet 12 of 12

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

#### NON PATENT LITERATURE DOCUMENTS

		HONT ATENT ETTERATORE DOCUMENTO	- , <sub>,</sub>
Examiner	Cite		T'
Initials*	No.	Description	
X	C112	YIP, K.F. et al., "Use of High-Performance Liquid Chromatography in the Preparation of Flavin Adenine Dinucleotide Analyte Conjugates," J. of Chromatography 326, 301-310, Elsevier Science Publishers B.V., Amsterdam (1985).	
	C113	Cyclophosphamide Metabolism: Impact on Pharmacokinetics and Antitumor Activity," <i>J. Pharm. Exp. Ther.</i> 288(3), 928-937, The American Society for Pharmacology and Experimental Therapeutics (March 1999).	٠
d	C114	YULE, S.M. et al., "The Effect of Fluconazole on Cyclophosphamide Metabolism in Children," <i>Drug Metabolism and Disposition</i> 27(3), 417-421, The American Society for Pharmacology and Experimental Therapeutics (March 1999).	

	<u> </u>						
Examiner		111 /		Date	2/	./.	
Signature	On	11101	4	Considered	7/1/	106	
			177				

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant is to place a check mark here if English language translation is attached.



Sheet 1 of 1

· · · · · · · · · · · · · · · · · · ·	
Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

Examiner	Cite		T
Initials*	No.	Description	
Ken	C115	DECHANT, K.L., et al., "Ifosfamide/Mesna. A Review of its Antineoplastic Activity, Pharmacokinetic Properties and Therapeutic Efficacy in Cancer," <i>Drugs 42</i> (3), 428-467 Adis International Limited (1991)	
Cu	C116	JAIN, M., et al., "Sulfonyl-Containing Aldophosphamide Analogues as Novel Anticancer Prodrugs Targeted against Cyclophosphamide-Resistant Tumor Cell Lines," <i>J. Med. Chem.</i> 47, 3843-3852 American Chemical Society (July 2004)	-
pr	C117	Prosecution history of Dang, Q., et al., U.S. Application No. 09/389,698, filed September 3, 1999, now patented as 6,489,476 B1	
•	C118		
	C119		
	C120		
	C121		
	C122		-
	C123		-

		4891/6_1.DOC	
Examiner	11/2/10-	Date //	
Signature / Om	Malex	Considered 1/11/6%	
		7"/	

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant is to place a check mark here if English language translation is attached.



Sheet 1 of 2

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

#### **U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Document Number	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant	Relevant Pages
	A14				
•	A15				
	A16				
	A17		-		
	A18				
	A19				
	A20				
	A21				
	A22				
	A23				
	A24				
	A25	<del></del>	· · · · · · · · · · · · · · · · · · ·		
,	A26				

#### **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Document (Cty code-number-kind)	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant	Relevant Pages	T,	
TOM	B4	EP 0 072 987 A1	08-13-1982	Henkel Kommanditgesellschaft auf Aktien			
	B5						
	B6						
	B7						
	B8		-				
	B9						
	B10						
	B11						
	B12						
	B13						
	B14						

			491019_1.DOC
Examiner Signature On /	// // // / / / / / / / / / / / / / / /	Date Considered 3	11/05

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant is to place a check mark here if English language translation is attached.



Sheet 2 of 2

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

Examiner	Cite		T
Initials*	No.	Description	'
TCU	C118	Delphion English-language abstract of European Patent Publication No. 0 072 987 A1, 2 pages, accessed on October 20, 2005 at https://www.delphion.com/details?pn=EP00072987A1&s-FAMILY=1	
gr	C119	Unverified English-language translation of European Patent Publication No. 0 072 987 A1, 13 pages	
	C120		
	C121		
	C122		
	C123		
	C124		
	C125		
	C126		
	C127		

	~						
Examiner Signature	Jom	Mc	Kenzia	Date Considered	3/11/	06	
(		, , , , ,					

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant is to place a check mark here if English language translation is attached.